XTX Topco Ltd Sells 102,265 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

XTX Topco Ltd trimmed its holdings in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 42.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 140,576 shares of the company’s stock after selling 102,265 shares during the period. XTX Topco Ltd owned 0.11% of Karyopharm Therapeutics worth $122,000 at the end of the most recent quarter.

Separately, Acadian Asset Management LLC acquired a new stake in Karyopharm Therapeutics during the 2nd quarter worth $167,000. Institutional investors and hedge funds own 66.44% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on KPTI. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. Royal Bank of Canada restated an “outperform” rating and set a $3.00 target price on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th. StockNews.com upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Finally, Robert W. Baird cut their price target on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $4.80.

Karyopharm Therapeutics Price Performance

Shares of Karyopharm Therapeutics stock opened at $0.76 on Wednesday. The company has a market capitalization of $94.38 million, a P/E ratio of -0.60 and a beta of 0.20. The business has a 50-day moving average of $0.81 and a two-hundred day moving average of $1.00. Karyopharm Therapeutics Inc. has a 1 year low of $0.62 and a 1 year high of $1.95.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Tuesday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.09. The business had revenue of $42.79 million for the quarter, compared to the consensus estimate of $36.07 million. On average, equities analysts anticipate that Karyopharm Therapeutics Inc. will post -0.93 EPS for the current fiscal year.

Karyopharm Therapeutics Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).